CTXR
Citius Pharmaceuticals, Inc.
There isn't enough reported data to score CTXR yet.
CTXR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CTXR's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
CTXR PE Valuation
CTXR has no meaningful PE right now: it lost money over the past year.
CTXR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CTXR's earnings and revenue to decline, though with profitability holding steady.
CTXR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$5.09 | +$0.91 |
| Q1 2025 | -$5.79 | +$0.21 |
| Q4 2024 | -$5.77 | +$0.73 |
| Q3 2024 | -$5.97 | -$0.47 |
| Q2 2024 | -$6.00 | -$0.75 |
| Q1 2024 | -$6.00 | -$0.75 |
| Q4 2023 | -$6.50 | -$1.75 |
| Q3 2023 | -$5.50 | +$0.25 |
CTXR is still losing money, but far less than before: $5.09 per share over the past year, against $19.25 at its worst in late 2019.
CTXR Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -785% | N/A |
| Q1 2026 | -1931% | N/A |
| Q4 2025 | -229% | N/A |
CTXR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$8.7M | -$3.3M |
| Q1 2026 | -$1.3M | +$3.2M |
| Q4 2025 | -$13M | -$8.3M |
| Q3 2025 | -$11.9M | -$6M |
| Q2 2025 | -$5.4M | +$3M |
| Q1 2025 | -$4.5M | +$3.2M |
| Q4 2024 | -$4.7M | +$1.4M |
| Q3 2024 | -$5.9M | +$887.5K |
CTXR has burned cash in almost every quarter: −$35M over the past year, against −$21M the year before.
CTXR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +3.8M shares |
| 1 year | +205% | +17.6M shares |
| 3 years | +347% | +20.3M shares |
| 5 years | +1077% | +23.9M shares |
CTXR has 26M diluted shares, up 205% from a year ago.
CTXR Net Leverage
CTXR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTXR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.6 | Neutral |
| Stochastic | 36.6 | Neutral |
CTXR's weekly RSI is 45 (neutral) and its Stochastic is 37 (neutral).
CTXR PE vs Healthcare Sector
CTXR has no meaningful PE right now: it lost money over the past year.
CTXR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.51 | 3.9% above |
| 20 week MA | $0.56 | 5.4% below |
| 50 week MA | $0.69 | 23% below |
| 100 week MA | $1.15 | 54% below |
| 200 week MA | $11.0 | 95% below |
CTXR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 95% below its 200-week average.
CTXR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.0 | $27.8 | +2.8% |
| 2021 | $27.8 | $42.0 | +51% |
| 2022 | $42.0 | $20.9 | -50% |
| 2023 | $20.9 | $18.9 | -9.6% |
| 2024 | $18.9 | $3.68 | -81% |
| 2025 | $3.68 | $0.84 | -77% |
| 2026 YTD | $0.84 | $0.53 | -37% |
CTXR has finished four years in a row lower, and it's down 37% so far in 2026.